Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYNJ2 | O15056 | 1/20 | 0.39 |
| ▸ | PYGB | P11216 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18214230 | 1.00 | SYNJ2 (0.39) | SYNJ2PYGBGAAL3MBTL1ALDH1A1 | |
| SCHEMBL18214252 | 1.00 | SYNJ2 (0.39) | SYNJ2PYGBGAAL3MBTL1ALDH1A1 | |
| SCHEMBL18214277 | 0.89 | LGALS3 (0.42) | SYNJ2LGALS3 | |
| SCHEMBL20161451 | 0.86 | PYGB (0.38) | SYNJ2PYGBGAAL3MBTL1ALDH1A1 | |
| SCHEMBL20161404 | 0.86 | PYGB (0.38) | SYNJ2PYGBGAAL3MBTL1ALDH1A1 | |
| SCHEMBL20161668 | 0.86 | PYGB (0.38) | SYNJ2PYGBGAAL3MBTL1ALDH1A1 | |
| SCHEMBL20161667 | 0.85 | PYGB (0.38) | SYNJ2PYGBGAAL3MBTL1ALDH1A1 | |
| SCHEMBL20158773 | 0.83 | FUCA1 (0.33) | ALDH1A1 | |
| SCHEMBL18214269 | 0.82 | PYGB (0.42) | PYGBGAAALDH1A1THRBMAPT | |
| SCHEMBL20158767 | 0.82 | PYGB (0.42) | PYGBGAAALDH1A1THRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | SYNJ2 4129/4885PYGB 3409/4885GAA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.